Drugs / Raludotatug Deruxtecan
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04707248 | Dec 2020 → Apr 2026 overdue | ovarian neoplasm, renal cell carcinoma | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06843447 | Apr 2025 → Mar 2029 expected | ovarian carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT06780085 | May 2025 → Mar 2032 expected | non-small cell lung carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06864169 | Apr 2025 → Aug 2026 overdue | digestive system cancer | Merck Sharp & Dohme LLC | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06660654 | Jan 2025 → Sep 2027 expected | metastatic neoplasm | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06161025 | Feb 2024 → Feb 2028 expected | — | Daiichi Sankyo | Recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Raludotatug Deruxtecan | “This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC).” NCT04707248 ↗5“A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer” NCT06161025 ↗ |
| Known as | DS-6000a | “This clinical trial will evaluate raludotatug deruxtecan (R-DXd; DS-6000a) in participants with advanced renal cell carcinoma (RCC) and ovarian cancer (OVC).” NCT04707248 ↗ |
| Known as | R-DXd | “The study medicine raludotatug deruxtecan (also called MK-5909, R-DXd, or DS-6000a) is a type of medicine called an antibody-drug conjugate (ADC).” NCT06864169 ↗ |
| Action | Deplete | “An ADC attaches to specific targets on cancers cells and delivers treatment to destroy those cells.” NCT06780085 ↗ |
| Modality | Other / unclassified | “R-DXd is an antibody drug conjugate” NCT04707248 ↗ |
| Route | Intravenous | “Intravenous administration at doses starting at 1.6 mg/kg on Day 1 of Cycle 1” NCT04707248 ↗ |
| Target | CDH6 | “R-DXd is an antibody drug conjugate that specifically binds to CDH6 on the cell surface of target cells” NCT04707248 ↗ |